 A 2 arm 1 Active, 1 Active Control study is to compare the safety and efficacy of different induction agents alemtuzumab, basiliximab or rabbit anti-thymocyte globulin in renal transplant recipients treated with tacrolimus, MMF and a rapid steroid withdrawal. 